(via TheNewswire)

Vancouver, British Columbia, March 16, 2026 – TheNewswire - At the request of CIRO, Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.

The Company is a biotechnology company focused on discovering and developing medications and therapies to address mental health disorders, including nicotine addiction and posttraumatic stress disorder (PTSD). The Company’s objective is to use a blend of advanced technology with an elaborate infrastructure to speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions.  

Neither Canadian Securities Exchange (“CSE”) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

For further information please contact:

NOVERIS HEALTH SCIENCES INC.

Jason Birmingham

Chief Executive Officer  

Tel: +1 778-900-NVRS (6877)

Investor Relations Email: fair@noveris.health

Web: http://noveris.health

Copyright (c) 2026 TheNewswire - All rights reserved.